Turbine
Hungary
- Budapest
- 20/06/2023
- Series A
- $6,004,625
Turbine was founded for a simple reason; to understand complex cancers better than existing experimental tools in order to solve unmet oncology needs.
Through a multidisciplinary team that unites computer science and molecular biology, and the world's most intricate simulation of cell behavior, we identify treatment options for the 70% of cancers that are currently unexplored.
We use our platform, the Simulated Cell™, to uncover novel biological insights across both new and known targets. This allows us to provide a fresh biological context, define responsive patient populations, and design drug combination approaches that diminish resistance.
With a process proven by clinical stage predictions and a proprietary pipeline, we continue our mission of unlocking cancer complexity to deliver next-generation precision therapeutics.
- Industry Biotechnology Research
- Website https://turbine.ai/
- LinkedIn https://www.linkedin.com/company/turbine-inc/
dazzle ai | $8,000,000 | (Jan 7, 2026)
Tesoro XP, Inc. | $5,400,000 | (Jan 7, 2026)
Lemon Slice | $10,500,000 | (Jan 7, 2026)
Array Labs | $20,000,000 | (Jan 7, 2026)
Lyte | $107,000,000 | (Jan 7, 2026)
Lucidean | $18,000,000 | (Jan 7, 2026)
CHAMP | $55,000,000 | (Jan 7, 2026)
Truemed | $34,000,000 | (Jan 7, 2026)
Coinbax | $4,200,000 | (Jan 7, 2026)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ciphero | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)